Market Place
Sourcing Support
Monte Rosa Adds Dr. Eric Hughes To Board Of Directors
13 Dec 2024 //
GLOBENEWSWIRE
Monte Rosa Therapeutics Presents Data on CDK2-directed Degraders
11 Dec 2024 //
GLOBENEWSWIRE
Monte Rosa Closes Global License Agreement With Novartis
11 Dec 2024 //
GLOBENEWSWIRE
Monte Rosa Provides Update on MRT-2359 Study in Solid Tumors
05 Dec 2024 //
GLOBENEWSWIRE
Monte Rosa Therapeutics to Participate in Piper Sandler Conference
26 Nov 2024 //
GLOBENEWSWIRE
Monte Rosa to Participate in the Jefferies London Health Conference
13 Nov 2024 //
GLOBENEWSWIRE
Monte Rosa Therapeutics Q3 2024 Results & Corporate Update
07 Nov 2024 //
GLOBENEWSWIRE
Novartis Inks $2.2B Molecular Glue Deal With Monte Rosa"
29 Oct 2024 //
REUTERS
Monte Rosa Presents Data on Cyclin E1 Degraders at EORTC
23 Oct 2024 //
GLOBENEWSWIRE
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
28 Aug 2024 //
GLOBENEWSWIRE
Monte Rosa Therapeutics Doses First Participants In MRT-6160 Phase 1 Study
19 Aug 2024 //
GLOBENEWSWIRE
Monte Rosa Therapeutics Announces Q2 2024 Results And Corporate Update
08 Aug 2024 //
GLOBENEWSWIRE
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
08 Jul 2024 //
GLOBENEWSWIRE
Monte Rosa Provides Development Progress Updates on MRT-2359 & MRT-6160
27 Jun 2024 //
GLOBENEWSWIRE
Monte Rosa Presents MRT-6160 RA Preclinical Data At EULAR
14 Jun 2024 //
GLOBENEWSWIRE
Monte Rosa Therapeutics Announces Leadership Team Promotions
30 May 2024 //
GLOBENEWSWIRE
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
30 May 2024 //
GLOBENEWSWIRE
Monte Rosa Highlights MRT-6160 IBD Potential At DDW 2024
21 May 2024 //
GLOBENEWSWIRE
With a fresh $100M, Monte Rosa CEO details plans to move several molecular glues
21 May 2024 //
ENDPTS
Monte Rosa Prices $100M Public Offering Of Shares
16 May 2024 //
GLOBENEWSWIRE
Monte Rosa’s $100M offering; Alexion to hand back preclinical program to Zealand
16 May 2024 //
ENDPTS
Monte Rosa Announces Proposed Public Offering Of Stock, Warrants
15 May 2024 //
GLOBENEWSWIRE
Monte Rosa Therapeutics Q1 2024 Financials And Update
09 May 2024 //
GLOBENEWSWIRE
Monte Rosa CSO Owen Wallace Departs
02 May 2024 //
GLOBENEWSWIRE
Monte Rosa Announces Fourth Quarter and Full Year 2023 Financial Results
14 Mar 2024 //
GLOBENEWSWIRE
Monte Rosa Announces Initiation of IND Enabling Studies for MRT-8102
11 Mar 2024 //
GLOBENEWSWIRE
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
31 Jan 2024 //
GLOBENEWSWIRE
Monte Rosa Provides Corporate Update and Key Anticipated Milestones for 2024
08 Jan 2024 //
GLOBENEWSWIRE
Monte Rosa to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
21 Nov 2023 //
GLOBENEWSWIRE
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Trio of biotechs toss programs to discard pile
09 Nov 2023 //
FIERCE BIOTECH
Monte Rosa Presents Data at ACR Convergence Demonstrating Potential of MRT-6160
07 Nov 2023 //
GLOBENEWSWIRE
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
27 Oct 2023 //
GLOBENEWSWIRE
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering
26 Oct 2023 //
GLOBENEWSWIRE
Roche signs $2.5B deal with Boston`s Monte Rosa Therapeutics
18 Oct 2023 //
FIERCE BIOTECH
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359
17 Oct 2023 //
GLOBENEWSWIRE
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors
26 Jul 2023 //
GLOBENEWSWIRE
Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences
30 May 2023 //
GLOBENEWSWIRE
Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160
23 May 2023 //
GLOBENEWSWIRE
Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Monte Rosa Presents Preclinical Data from GSPT1 Degrader Program
17 Apr 2023 //
GLOBENEWSWIRE
Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors
23 Mar 2023 //
GLOBENEWSWIRE
Monte Rosa Announces Fourth Quarter and Full Year 2022 Financial Results
16 Mar 2023 //
GLOBENEWSWIRE
Monte Rosa Therapeutics to Present at Upcoming Investor Conferences
03 Feb 2023 //
GLOBENEWSWIRE
Monte Rosa Outlines Progress Across Portfolio of Molecular Glue Degraders
09 Jan 2023 //
GLOBENEWSWIRE
Monte Rosa to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
GLOBENEWSWIRE
Monte Rosa Announces First Patient Dosed in Ph1/2 Trial Evaluating MRT-2359
01 Nov 2022 //
GLOBENEWSWIRE
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences
31 Oct 2022 //
GLOBENEWSWIRE
Monte Rosa to Present at 5th Annual Targeted Protein Degradation Summit
20 Oct 2022 //
GLOBENEWSWIRE
Monte Rosa Announces FDA Clearance of InvestigationalNDA for MRT-2359
06 Sep 2022 //
GLOBENEWSWIRE
Monte Rosa Therapeutics Reports Q2 2022 Rusult and Business Updates
11 Aug 2022 //
GLOBENEWSWIRE
Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results
11 May 2022 //
GLOBENEWSWIRE
Monte Rosa Therapeutics Presents Preclinical Data of MRT-2359 at AACR
08 Apr 2022 //
GLOBENEWSWIRE
Monte Rosa Reports Q4 and Full Year 2021 Financial Results
29 Mar 2022 //
PRESS RELEASE
Monte Rosa Tx Announces Participation in Upcoming Investor Conferences
03 Feb 2022 //
PRESS RELEASE
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences
03 Feb 2022 //
GLOBENEWSWIRE
Monte Rosa Therapeutics and Yeda, Announce License and Research Collaboration
25 Jan 2022 //
PRESS RELEASE
Monte Rosa, Yeda Collaborate for Discovery of Covalent Molecular Glue Degraders
25 Jan 2022 //
GLOBENEWSWIRE
